- Home
- LUCD vs ABOS Comparison
LUCD vs ABOS Comparison
Compare LUCD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | ABOS |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.5M | 155.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCD | ABOS |
|---|---|---|
| Price | $1.39 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.94 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 743.4K | 277.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $155.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.95 | $0.86 |
| 52 Week High | $1.80 | $3.50 |
Technical Indicators
Market Signals| Indicator | LUCD | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 65.35 |
| Support Level | $1.01 | $1.21 |
| Resistance Level | $1.52 | N/A |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 47.22 | 80.79 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.